CoreRx, Societal CDMO, and Bend Bioscience Unite Under Bend Bioscience Brand

• CoreRx, Societal CDMO, and Bend Bioscience unite under the Bend Bioscience brand.

• The merger creates a comprehensive contract development and manufacturing organization (CDMO) with end-to-end services.

CoreRx, Societal CDMO, and Bend Bioscience have officially merged under the Bend Bioscience brand, forming a fully integrated contract development and manufacturing organization (CDMO). This merger combines the distinct strengths of all three companies to offer an extensive range of services from drug development to commercialization.

CoreRx, known for its innovation in formulation development, brings its expertise in creating complex drug delivery systems. Societal CDMO, a specialist in scalable manufacturing and commercial production, enhances the group’s capabilities with its proven reliability in cGMP manufacturing and supply chain management.

Commenting on the unification, Owen Murray, CEO of Bend Bioscience, stated, “This merger is not just about combining resources; it’s about building on the strengths of CoreRx’s advanced formulation development, Societal CDMO’s respected manufacturing capabilities, and Bend Bioscience’s leadership in scientific research.”

The decision to consolidate under the Bend Bioscience name reflects a focus on innovation and technical excellence. This move is expected to increase operational efficiencies and provide clients with comprehensive support in bringing therapies to market faster.